AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.

Int J Infect Dis

Department of Medicine, Division of Cardiovascular Disease, University of California San Diego Health System, 9444 Medical Center Dr, La Jolla, CA 92107, USA; Department of Medicine, Division of Infectious Diseases, University of Colorado Denver School of Medicine, Denver, Colorado, USA. Electronic address:

Published: October 2013

Objective: To retrospectively investigate the outcomes of patients with AIDS-associated Kaposi sarcoma (AIDS-KS) after initiation of antiretroviral therapy (ART), under routine practice conditions, at a university-affiliated hospital in urban Zimbabwe.

Background: While studies from developed nations have demonstrated excellent outcomes for AIDS-KS patients treated with ART, few studies have examined the outcomes of African AIDS-KS patients after starting therapy.

Methods: A retrospective cohort of 124 AIDS patients initiating ART under routine practice conditions was studied. Thirty-one patients with AIDS-KS were matched 1:3 to 93 AIDS patients without KS (non-KS). The primary outcome was loss-to-care after initiation of therapy. Multivariate analysis was performed to identify significant predictors of loss-to-care. The percent change in weight at 6 months after starting ART was a secondary outcome. A sub-group analysis evaluated differences in pre-treatment variables between AIDS-KS patients retained-in-care compared to those lost-to-care.

Results: AIDS-KS patients had significantly greater 2-year proportional loss-to-care than matched non-KS AIDS patients (26.4% vs. 9.5%; p = 0.01) after initiation of ART. In multivariate analysis, the presence of KS (p = 0.02) was the only significant predictor of loss-to-care. AIDS-KS patients had significantly less weight gain after starting ART than non-KS AIDS patients (+3.4% vs. +6.4%; p = 0.03). AIDS-KS patients retained-in-care had significantly higher pre-treatment CD4+ lymphocyte counts than AIDS-KS patients lost-to-care (223 vs. 110 cells/mm(3); p = 0.04).

Conclusions: In this retrospective study, AIDS-KS patients experienced significantly worse outcomes than matched non-KS AIDS patients after initiation of ART. AIDS-KS patients with higher pre-treatment CD4+ lymphocyte counts were more likely to be retained in care.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2013.04.011DOI Listing

Publication Analysis

Top Keywords

aids-ks patients
36
aids patients
20
patients
16
non-ks aids
12
aids-ks
11
aids-associated kaposi
8
kaposi sarcoma
8
initiation antiretroviral
8
antiretroviral therapy
8
university-affiliated hospital
8

Similar Publications

Article Synopsis
  • Kaposi's sarcoma (KS) is a soft tissue lesion linked to HHV-8 infection, often seen in immunocompromised patients, especially those with AIDS, and has a high mortality rate.
  • A case report details a patient with AIDS-KS who relapsed after initial chemotherapy, but achieved complete remission with a PD-1 inhibitor, indicating its effectiveness in treatment.
  • The PD-1 inhibitor was well-tolerated, improved the patient's immune system, and suggests a promising approach for managing AIDS-KS.
View Article and Find Full Text PDF

Kaposi sarcoma (KS) is the most common cancer in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (AIDS). In 1994, Chang and Moore discovered Kaposi sarcoma associated herpesvirus for the first time in KS lesions in AIDS patients. KS is a low-grade mesenchymal neoplasm of blood and lymphatic vessels that primarily affects the skin, although the disease may become disseminated to the lymphatic system, lungs, airways, or abdominal viscera.

View Article and Find Full Text PDF

Objectives: Despite the improved survival of patients with AIDS and Kaposi's sarcoma (KS), competing events are a non-negligible issue affecting the survival of such patients. In this study, we explored the prognostic factors of KS-specific and non-KS-specific mortality in patients with AIDS-related KS (AIDS-KS), accounting for competing risk.

Methods: We identified 17 103 patients with AIDS-KS aged 18-65 years between 1980 and 2016 from the Surveillance, Epidemiology, and End Results (SEER) 18 registry database.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of serum biomarkers related to inflammation, immune activation, and angiogenesis in identifying limited-stage AIDS-related Kaposi sarcoma patients who may need additional chemotherapy alongside antiretroviral therapy (ART).
  • It analyzes serum samples from a trial that tested the efficacy of adding oral etoposide chemotherapy to ART in treatment-naïve patients with limited-stage AIDS-KS, focusing on baseline biomarker levels and how they correlate with disease progression and treatment response.
  • Results indicated that higher levels of certain biomarkers like C-reactive protein (CRP) and interleukin-10 (IL-10) were linked to worse outcomes, suggesting that monitoring these biomarkers could help tailor treatment plans for better management of AIDS-K
View Article and Find Full Text PDF

BACKGROUND As an AIDS-defining illness, the neoplasm Kaposi sarcoma (KS) classically presents as cutaneous lesions that are often associated with periorbital edema. This association with KS is important because it frequently leads to the misuse of steroids in HIV-infected patients. This report presents 2 cases of AIDS-related Kaposi sarcoma (AIDS-KS) associated with severe steroid-unresponsive periorbital lymphedema that responded to chemotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!